You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections

    SBC: Zymeron Corporation            Topic: NIAID

    CytomegalovirusCMVis a very common intrauterine infectionaffecting approximately one in everychildrenThe overall disease burden in the US with congenital CMV was estimated at $billion annuallyCMV is also a cause of serious morbidity and fatal infections in immunocompromised patientsThere is currently no generally accepted therapy and developing a CMV vaccine is high priorityCurrently CMV trials re ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Whole-organ bioreactor with integrated nondestructive 3D molecular imaging

    SBC: Sonovol, Inc.            Topic: NHLBI

    Abstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome editing technologies, such as CRISPR/Cas9 provide a rapid, and targeted means of both knocking out gene expression and knocking in gene modifications. Since our initial Phase I submission, the utility of CRISPR technology has expanded beyond the generation of cell lines, to forward genetic screening, in vivo manipulation of gene expression and even human therapeutics. Phase I ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. SBIR Phase II: Protein A Membrane Columns for Rapid Protein Purification

    SBC: Purilogics, LLC            Topic: 400

    Project Summary This SBIR Urgent Competitive Revision will develop the first affinity membrane to purify therapeutic mRNA with high selectivity and throughput. mRNA-based pharmaceuticals have potential to address a wide variety of pathologies. mRNA-based vaccines can increase safety and dramatically shorten development timelines in pandemic scenarios. A number of mRNA-based COVID-19 vaccines are u ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Software for predicting a drug's potential to cause acute kidney injury

    SBC: DILIsym Services, Inc.            Topic: 400

    The goal of this project is to develop novel technology for predicting drug-induced kidney injury such as caused by systemic antimicrobials, diuretics, anticancer agents, and anti-inflammatory drugs. Drugs cause approximately 20 percent of community- and hospital- acquired episodes of acute renal failure, but the incidence in older adults may be as high as 60 percent. A significant problem is that ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Developing, Testing and Validating a Wearable Alcohol Biosensor

    SBC: Clinitech, LLC            Topic: 450

    1 PROJECT SUMMARY2 This application for a Phase II SBIR award extends the successful completion of Phase I and represents a 3 collaboration between Clinitech, LLC and McLean Hospital/Harvard Medical School to continue the4 development of a wearable biosensor for detecting alcohol in the interstitial fluid of humans. Excessive use of5 alcohol accounts for much of the public health burden related to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a New Carbohydrate-based Anticoagulant Drug

    SBC: Glycan Therapeutics LLC            Topic: NHLBI

    Low molecular weight heparins (LMWHs) are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Low cost retinal optical coherence tomography for point of care use

    SBC: Lumedica, Inc            Topic: NEI

    The objective of this research is to create a clinical prototype of a new optical coherence tomography (OCT) system suitable for diagnostic retinal imaging at the point of care. The target system price will be one third the price of currently available research OCT systems while providing performance comparable to other entry level OCT imaging systems. By breaking the $15,000 system barrier we wil ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    Abstract Polychromatic flow cytometry (FC) is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells. Dyes used for FC typically exhibit broad fluorescent emission bands with full-width-at-half-maximum (fwhm) values of 50–80 nm. This limits the maximum number of dyes, and thus the nu ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government